WO2008049902A3 - Inhibiteurs de vegfr3 - Google Patents

Inhibiteurs de vegfr3 Download PDF

Info

Publication number
WO2008049902A3
WO2008049902A3 PCT/EP2007/061499 EP2007061499W WO2008049902A3 WO 2008049902 A3 WO2008049902 A3 WO 2008049902A3 EP 2007061499 W EP2007061499 W EP 2007061499W WO 2008049902 A3 WO2008049902 A3 WO 2008049902A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinazoline derivatives
vegfr3
inhibitors
macrocyclic quinazoline
macrocyclic
Prior art date
Application number
PCT/EP2007/061499
Other languages
English (en)
Other versions
WO2008049902A2 (fr
Inventor
Timothy Pietro Suren Perera
Matthias Luc A Versele
Martin John Page
Original Assignee
Janssen Pharmaceutica Nv
Timothy Pietro Suren Perera
Matthias Luc A Versele
Martin John Page
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Timothy Pietro Suren Perera, Matthias Luc A Versele, Martin John Page filed Critical Janssen Pharmaceutica Nv
Priority to JP2009533850A priority Critical patent/JP2010507626A/ja
Priority to BRPI0718061-6A priority patent/BRPI0718061A2/pt
Priority to CA002664148A priority patent/CA2664148A1/fr
Priority to EP07821862A priority patent/EP2077845A2/fr
Priority to AU2007310843A priority patent/AU2007310843A1/en
Priority to EA200970419A priority patent/EA200970419A1/ru
Priority to MX2009004436A priority patent/MX2009004436A/es
Publication of WO2008049902A2 publication Critical patent/WO2008049902A2/fr
Publication of WO2008049902A3 publication Critical patent/WO2008049902A3/fr
Priority to IL198346A priority patent/IL198346A0/en
Priority to NO20092045A priority patent/NO20092045L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur l'utilisation de certains des dérivés de la quinazoline macrocyclique décrits dans la publication de la demande internationale PCT WO2004/105765 en tant qu'inhibiteurs d'activités biologiques à médiation par VEGFR3, notamment les activités qui sont à médiation par les ligands de VEGFR3, VEGF-C et/ou VEGF-D.
PCT/EP2007/061499 2006-10-27 2007-10-25 Inhibiteurs de vegfr3 WO2008049902A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2009533850A JP2010507626A (ja) 2006-10-27 2007-10-25 Ｖｅｇｆｒ３阻害剤としての大環状キナゾリン誘導体
BRPI0718061-6A BRPI0718061A2 (pt) 2006-10-27 2007-10-25 Inibidores de vegfr3
CA002664148A CA2664148A1 (fr) 2006-10-27 2007-10-25 Inhibiteurs de vegfr3
EP07821862A EP2077845A2 (fr) 2006-10-27 2007-10-25 Dérivés de quinazoline macrocycliques comme inhibiteurs de vegfr3
AU2007310843A AU2007310843A1 (en) 2006-10-27 2007-10-25 Macrocyclic quinazoline derivatives as VEGFR3 inhibitors
EA200970419A EA200970419A1 (ru) 2006-10-27 2007-10-25 Микроциклические хиназолиновые производные в качестве ингибиторов vegfr3
MX2009004436A MX2009004436A (es) 2006-10-27 2007-10-25 Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3.
IL198346A IL198346A0 (en) 2006-10-27 2009-04-23 Macrocyclic quinazoline derivatives as vegfr3 inhibitors
NO20092045A NO20092045L (no) 2006-10-27 2009-05-26 Makrosykliske quinazolinderivater som VEGFR3-inhibitorer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US86319806P 2006-10-27 2006-10-27
US60/863,198 2006-10-27
EP06123056 2006-10-27
EP06123056.1 2006-10-27
US97621007P 2007-09-28 2007-09-28
US60/976,210 2007-09-28

Publications (2)

Publication Number Publication Date
WO2008049902A2 WO2008049902A2 (fr) 2008-05-02
WO2008049902A3 true WO2008049902A3 (fr) 2008-10-02

Family

ID=39324960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/061499 WO2008049902A2 (fr) 2006-10-27 2007-10-25 Inhibiteurs de vegfr3

Country Status (11)

Country Link
EP (1) EP2077845A2 (fr)
JP (1) JP2010507626A (fr)
KR (1) KR20090089849A (fr)
AU (1) AU2007310843A1 (fr)
BR (1) BRPI0718061A2 (fr)
CA (1) CA2664148A1 (fr)
EA (1) EA200970419A1 (fr)
IL (1) IL198346A0 (fr)
MX (1) MX2009004436A (fr)
NO (1) NO20092045L (fr)
WO (1) WO2008049902A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
WO2008006884A2 (fr) 2006-07-13 2008-01-17 Janssen Pharmaceutica N.V. DÉRIVÉs de quinazoline de type mtki
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
JP2013523843A (ja) * 2010-04-15 2013-06-17 ベジェニクス ピーティーワイ リミテッド Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療
RU2598840C2 (ru) 2011-05-19 2016-09-27 Фундасион Сентро Насиональ Де Инвестигасионес Онколохикас Карлос Iii Новые соединения

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105765A1 (fr) * 2003-05-27 2004-12-09 Janssen Pharmaceutica N.V. Derives de quinazoline macrocyclique utilises comme agents antiproliferatifs
WO2005058913A1 (fr) * 2003-12-18 2005-06-30 Janssen Pharmaceutica N.V. Anti-proliferants a base de derives pyrido- et pyrimidopyrimidine
WO2006061417A2 (fr) * 2004-12-08 2006-06-15 Janssen Pharmaceutica N.V. Derives de quinazoline mtki

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105765A1 (fr) * 2003-05-27 2004-12-09 Janssen Pharmaceutica N.V. Derives de quinazoline macrocyclique utilises comme agents antiproliferatifs
WO2005058913A1 (fr) * 2003-12-18 2005-06-30 Janssen Pharmaceutica N.V. Anti-proliferants a base de derives pyrido- et pyrimidopyrimidine
WO2006061417A2 (fr) * 2004-12-08 2006-06-15 Janssen Pharmaceutica N.V. Derives de quinazoline mtki

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIARDIELLO F ET AL: "EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN LATE STAGE CLINICAL TRIALS", EXPERT OPINION ON EMERGING DRUGS, ASHLEY PUBLICATIONS, GB, vol. 8, no. 2, 2003, pages 501 - 514, XP009052597, ISSN: 1472-8214 *
UNDERINER T L ET AL: "DEVELOPMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR) KINASE INHIBITORS AS ANTI-ANGIOGENIC AGENTS IN CANCER THERAPY", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 11, 2004, pages 731 - 745, XP008056187, ISSN: 0929-8673 *
WEDGE STEPHEN R ET AL: "ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration", CANCER RESEARCH, vol. 62, no. 16, 15 August 2002 (2002-08-15), pages 4645 - 4655, XP002425560, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
EP2077845A2 (fr) 2009-07-15
IL198346A0 (en) 2010-02-17
BRPI0718061A2 (pt) 2013-11-05
KR20090089849A (ko) 2009-08-24
EA200970419A1 (ru) 2009-10-30
WO2008049902A2 (fr) 2008-05-02
JP2010507626A (ja) 2010-03-11
CA2664148A1 (fr) 2008-05-02
NO20092045L (no) 2009-06-26
AU2007310843A1 (en) 2008-05-02
MX2009004436A (es) 2009-05-22

Similar Documents

Publication Publication Date Title
MY170509A (en) Activin-actrii antagonists for use in treating anemia
WO2008094708A3 (fr) Antagonistes de l'activine-actriia et leurs utilisations dans le traitement ou la prévention du cancer du sein
WO2009115572A3 (fr) Nouveaux composés hétérocycliques et leurs utilisations
ZA200805247B (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
WO2009006389A3 (fr) Composés utiles en tant qu'inhibiteurs de la kinase raf
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
EP2532657A3 (fr) Composés et procédés d'utilisation
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
WO2008121767A3 (fr) Polypeptides cousus
WO2009158015A3 (fr) Antagonistes d’actriib et utilisations pour augmenter les taux d’érythrocytes
WO2006091459A3 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
WO2008098104A8 (fr) Inhibiteurs de l'activité de akt
MX343042B (es) Compuestos heteroarilicos biciclicos.
WO2009077471A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2007067506A3 (fr) Inhibiteurs d'erbb kinase de 2-pyrimidinyl-pyrazolopyridine
IL191137A0 (en) Polycation-polyanion complexes, compositions and methods of use thereof
WO2008097561A8 (fr) Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation
WO2007059202A3 (fr) Derives de pyrazolyluree utilisables dans le traitement du cancer
EP2617431A3 (fr) Inhibiteurs polypeptidiques de la kinase hsp27 et leurs utilisations
WO2007129226A3 (fr) Traitement de troubles cellulaires prolifératifs
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2009129267A3 (fr) Inhibiteurs de petites molécules du domaine d'homologie de la pleckstrine, et leurs méthodes d'utilisation
WO2008086462A3 (fr) Dérivés de quinalozine substitués par amino en tant qu'inhibiteurs de la voie b-caténine/tcf-4 et agents de traitement du cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780039993.1

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 575617

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12009500515

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2664148

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007821862

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009040555

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 2009533850

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 198346

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004436

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 818/MUMNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07821862

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020097009081

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007310843

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200970419

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2007310843

Country of ref document: AU

Date of ref document: 20071025

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0718061

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090427